Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies

@inproceedings{Hiniker2013ComparativeUO,
  title={Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies},
  author={Annie Hiniker and Brianne H Daniels and Hyoung Sik Lee and Marta Margeta},
  booktitle={Acta neuropathologica communications},
  year={2013}
}
BackgroundInclusion body myositis (IBM) is a slowly progressive inflammatory myopathy of the elderly that does not show significant clinical improvement in response to steroid therapy. Distinguishing IBM from polymyositis (PM) is clinically important since PM is steroid-responsive; however, the two conditions can show substantial histologic overlap.ResultsWe performed quantitative immunohistochemistry for (1) autophagic markers LC3 and p62 and (2) protein aggregation marker TDP-43 in 53… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 30 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 29 REFERENCES

Diagnostic value of markers of muscle degeneration in sporadic inclusion body myositis

  • Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology
  • 2011
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Inflammatory myopathies with mitochondrial pathology and protein aggregates

  • Journal of the Neurological Sciences
  • 2009
VIEW 9 EXCERPTS
HIGHLY INFLUENTIAL

Sporadic inclusion body myositis—diagnosis, pathogenesis and therapeutic strategies

  • Nature Clinical Practice Neurology
  • 2006
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Review: An update on inflammatory and autoimmune myopathies.

  • Neuropathology and applied neurobiology
  • 2011
VIEW 1 EXCERPT